Cellectis S.A.
$3.47▲ 12.66%(+$0.39)
TickerSpark Score
57/100
▌ Mixed
65
Valuation
40
Profitability
55
Growth
64
Health
60
Momentum
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a CMVLF research report →
52-Week Range59% of range
Low
$1.25
Current
$3.47
High
$5.04
Company Overviewwww.cellectis.com
About the company
Cellectis S. A. is a clinical-stage biotechnology firm dedicated to advancing immuno-oncology therapies.
- CEO
- Andre Choulika
- IPO
- 2014
- Employees
- 216
- HQ
- Paris, FR
Price Chart
+177.60% · this period
Valuation
- Market Cap
- $251.93M
- P/E
- -4.88
- P/S
- 3.47
- P/B
- 5.48
- EV/EBITDA
- -6.89
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 78.86%
- Op Margin
- -69.23%
- Net Margin
- -98.69%
- ROE
- -80.61%
- ROIC
- -27.24%
Growth & Income
- Revenue
- $75.92M · 82.91%
- Net Income
- $-70,343,970 · -91.35%
- EPS
- $-0.70 · -70.73%
- Op Income
- $-42,000,532
- FCF YoY
- -330.32%
Performance & Tape
- 52W High
- $5.04
- 52W Low
- $1.25
- 50D MA
- $4.41
- 200D MA
- $3.39
- Beta
- 2.77
- Avg Volume
- 3
Get TickerSpark's AI analysis on CMVLF
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Coverage · CMVLF
Our CMVLF coverage
Recent articles, reports, and earnings notes.
On-Demand Research
No research on CMVLF yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate CMVLF report →Internal Compare
Similar companies
Peers in the same neighborhood.